We first invested in PolyModels Hub in June 2024 as their sole investor to address a critical bottleneck in biopharma. After scientists have identified a target molecule for a new therapy, a vital but often overlooked part of bringing any new drug to market begins. How do we turn this into a finished product — a pill or an injectable — that can be manufactured reliably, safely, and at scale?

This is the 21st century, and we’re still building billion-dollar drugs on the equivalent of sticky notes and whiteboards: slow, manual wet-lab experimentation, driven by scientists’ tacit knowledge, no standardized processes to build on. The cost? Years added to development timelines. Millions in unnecessary spending. Delayed access to life-changing medicines for patients.

In the past year, the company, led by ex GlaxoSmithKline (GSK) scientists Antonio Benedetti and Charalampos Christodoulou, along with chemical turned software engineer Antonio Yankey, has earned the trust of four of the world’s top ten pharmaceutical companies. It supports them across multiple blockbuster programs through advanced modelling, simulation, and workflow management, all in one intuitive digital hub.

PolyModels Hub is quickly becoming a must-have for bringing new medicines to market. With PolyModels Hub, scientists and engineers can design, test, and improve drug development processes faster and more efficiently using data and automation. Its technology is delivering measurable results, helping biopharma save time, save hundreds of millions per drug, and deliver better medicines.

We are privileged to be day one partners with this deeply technical, domain-native group of engineers and scientists, with backgrounds at GSK, Eli Lilly, AstraZeneca, Johnson & Johnson, Amazon, and beyond. Currently, the company employs 20, of whom 1 in 4 has a PhD. The team has also developed a community of over 6,000 scientists and engineers by curating and sharing cutting-edge research and scientific insights, making them widely recognized among academic labs and industrial teams.

Today, PolyModels Hub announces a $9m Series A round led by Molten Ventures with participation from Marathon Venture Capital. The company is now bound to grow across geographies and functions, accelerating its vision to create the unified digital layer that supports the entire journey, from discovery to commercial manufacturing, with consistency, scientific rigor, and automation.

PolyModels Hub is quickly establishing itself as the critical enabler of modern drug development. The best of biopharma still runs on archaic processes. Outdated, manual wet-lab experiments can take days, weeks, or even months to complete, delaying patients' access to life-changing medicines. There is a monumental opportunity to lead this industry, and we believe PolyModels Hub has come along at precisely the right moment. 

PolyModels Hub is a team of pharma R&D and manufacturing specialists committed to accelerating the adoption of digital technologies in pharma process development

Learn more